Calliditas Therapeutics AB

Activities: Pharmaceutical

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon

China's National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression
Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Ingredients

Full details from Calliditas Therapeutics’ Phase 3 study released

Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon delayed release capsules in adults with Primary IgA nephropathy
Drug Delivery

Chinese NMPA accepts Calliditas' partner Everest Medicines NDA

Chronic kidney disease is one of the most serious public health problems in China, where IgAN is estimated by Everest to affect around five million people

Calliditas budesonide therapy approved to reduce proteinuria

Proteinuria is associated with IgAN, however it has not yet been established whether the therapy slows kidney function decline in patients with the condition
Regulatory

Calliditas receives fast track FDA designation for PBC candidate

The FDA program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions
Manufacturing

Calliditas and Everest Medicines enter $120m development deal in China

The agreement gives Everest Medicines exclusive rights to develop and commercialise Nefecon in five countries in East Asia
Subscribe now